The global protein engineering market size reached USD 3.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 8.2 Billion by 2033, exhibiting a growth rate (CAGR) of 9.5% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 3.6 Billion |
Market Forecast in 2033
|
USD 8.2 Billion |
Market Growth Rate 2025-2033 | 9.5% |
Protein engineering refers to the process of developing or changing a protein sequence to achieve the desired result. It involves the synthesis of new proteins or amendments in the existing structure or sequence and employs recombinant deoxyribonucleic acid (DNA) technology to alter amino acid sequences for novel and enhanced functions. It is widely utilized for the production of enzymes or proteins in large quantities for use in industrial settings. In recent years, researchers have successfully engineered a wide range of proteins tailored to medicine, research, industry, health, and biotechnology applications, which is escalating their demand across the globe.
The rising investments in synthetic biology and the improving focus toward protein-based drug development represent the primary factors driving the market growth. Additionally, there has been a significant shift toward protein therapeutics from non-protein drugs due to their associated positive clinical outcomes. This, in confluence with the widespread prevalence of protein-deficient diseases, is increasing the demand for protein engineering. Furthermore, several favorable initiatives undertaken by the government of various countries, such as increased funding for research and development (R&D) activities in the field of protein engineering, are propelling the market growth. Besides this, the advent of recombinant monoclonal antibodies (mAbs) and the increasing usage of monoclonal antibodies to treat various diseases, such as cancer and autoimmune diseases, are accelerating product adoption rates. Moreover, the ongoing research for applications of protein engineering in the agrochemical industry to generate enzymes with enhanced function to increase the crop yield or facilitate biofuel production is catalyzing the market growth. Other factors, including the escalating demand for personalized medicines, growing need for biosimilars and biologics, improving healthcare infrastructure, technological advancements, and product innovations, are also creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global protein engineering market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on product & services, protein type, technology and end user.
Breakup by Product & Services:
Breakup by Protein Type:
Breakup by Technology:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abzena Ltd., Agilent Technologies Inc., Amgen Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Codexis Inc., Danaher Corporation, Eli Lilly and Company, General Electric Company, Merck KGaA, Novo Nordisk A/S, PerkinElmer Inc., Thermo Fisher Scientific Inc. and Waters Corporation.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Product & Services, Protein Type, Technology, End User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Abzena Ltd., Agilent Technologies Inc., Amgen Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Codexis Inc., Danaher Corporation, Eli Lilly and Company, General Electric Company, Merck KGaA, Novo Nordisk A/S, PerkinElmer Inc., Thermo Fisher Scientific Inc. and Waters Corporation |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global protein engineering market was valued at USD 3.6 Billion in 2024.
We expect the global protein engineering market to exhibit a CAGR of 9.5% during 2025-2033.
The high prevalence of protein-deficient diseases, rising advancements in synthetic biology, and improving focus towards protein-based drug development are primarily driving the global protein engineering market.
The sudden outbreak of the COVID-19 pandemic has led to the growing adoption of protein engineering process for manufacturing novel vaccines to treat the coronavirus-infected patients and to prevent the risk of the infection.
Based on the product and services, the global protein engineering market has been divided into instruments, reagents, and services and software. Currently, instruments exhibit a clear dominance in the market.
Based on the protein type, the global protein engineering market can be categorized into insulin, monoclonal antibodies, coagulation factors, vaccines, growth factors, and others. Among these, monoclonal antibodies hold the majority of the total market share.
Based on the technology, the global protein engineering market has been segmented into irrational protein design and rational protein design. Currently, rational protein design represents the largest market share.
Based on the end user, the global protein engineering market can be bifurcated into pharmaceutical and biotechnology companies, academic research institutes, and contract research organizations. Among these, pharmaceutical and biotechnology companies currently account for the majority of the total market share.
On a regional level, the market has been classified into North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America, where North America currently dominates the global market.
Some of the major players in the global protein engineering market include Abzena Ltd., Agilent Technologies Inc., Amgen Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Codexis Inc., Danaher Corporation, Eli Lilly and Company, General Electric Company, Merck KGaA, Novo Nordisk A/S, PerkinElmer Inc., Thermo Fisher Scientific Inc., and Waters Corporation.